Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis

BACKGROUND: We explored whether clinically relevant baseline characteristics of patients with type 2 diabetes can modify the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on the risk of major adverse cardiovascular events (MACE)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cardiovasc Diabetol
Auteurs principaux: D’Andrea, Elvira, Kesselheim, Aaron S., Franklin, Jessica M., Jung, Emily H., Hey, Spencer Phillips, Patorno, Elisabetta
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7525990/
https://ncbi.nlm.nih.gov/pubmed/32993654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01133-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires